RxDoctor Payments Data

Jinyu Lu

Hematology & Oncology · Waterbury, CTNPI 1760861066

Payments from drug & device makers

What this record shows

This record is dominated by grants: $350 of the $373 with a category attached, or 93.9%. AstraZeneca accounts for 93.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.

$373in general payments, 2019–2025

Across 2 payments — averaging $186.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$350
  • Merck$23
$287,175in research payments, 2019–2025

Across 16 payments — averaging $17,948 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$181K
  • E.r. Squibb & Sons, L.L.C.$106K

What the payments were for

  • Grants$35094%
  • Food & beverage$236%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$350
Merck1$23

How this compares

$373 in reported general payments places this provider in the 30th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$49,208
Medicare patients
134
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib13$193,513
Tamoxifen Citrate93$2,235
Anastrozole76$1,223
Letrozole59$1,005
Exemestane15$980
LoperamideLoperamide Hcl34$423

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →